1. Home
  2. RIGL vs AKA Comparison

RIGL vs AKA Comparison

Compare RIGL & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • AKA
  • Stock Information
  • Founded
  • RIGL 1996
  • AKA 2018
  • Country
  • RIGL United States
  • AKA United States
  • Employees
  • RIGL N/A
  • AKA N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • AKA Catalog/Specialty Distribution
  • Sector
  • RIGL Health Care
  • AKA Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • AKA Nasdaq
  • Market Cap
  • RIGL 247.1M
  • AKA 251.5M
  • IPO Year
  • RIGL 2000
  • AKA 2021
  • Fundamental
  • Price
  • RIGL $26.04
  • AKA $21.40
  • Analyst Decision
  • RIGL Buy
  • AKA Buy
  • Analyst Count
  • RIGL 5
  • AKA 3
  • Target Price
  • RIGL $31.30
  • AKA $25.00
  • AVG Volume (30 Days)
  • RIGL 297.1K
  • AKA 11.2K
  • Earning Date
  • RIGL 11-07-2024
  • AKA 11-07-2024
  • Dividend Yield
  • RIGL N/A
  • AKA N/A
  • EPS Growth
  • RIGL N/A
  • AKA N/A
  • EPS
  • RIGL 0.22
  • AKA N/A
  • Revenue
  • RIGL $157,374,000.00
  • AKA $564,586,000.00
  • Revenue This Year
  • RIGL $38.26
  • AKA $4.56
  • Revenue Next Year
  • RIGL $24.21
  • AKA $3.92
  • P/E Ratio
  • RIGL $117.60
  • AKA N/A
  • Revenue Growth
  • RIGL 21.65
  • AKA 3.31
  • 52 Week Low
  • RIGL $7.48
  • AKA $7.00
  • 52 Week High
  • RIGL $29.82
  • AKA $33.73
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 70.96
  • AKA 48.17
  • Support Level
  • RIGL $22.33
  • AKA $18.19
  • Resistance Level
  • RIGL $29.16
  • AKA $21.29
  • Average True Range (ATR)
  • RIGL 2.34
  • AKA 1.95
  • MACD
  • RIGL 0.37
  • AKA -0.22
  • Stochastic Oscillator
  • RIGL 76.24
  • AKA 49.70

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About AKA a.k.a. Brands Holding Corp.

a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.

Share on Social Networks: